Therapeutic Specialties Archives | Page 2 of 28 | Certara

Press Coverage

2025 cell and gene challenges: Scalability, supply chain and manufacturing

Explore insights on 2025 challenges in cell and gene therapy, including commercial viability, with expert…

CertaraFebruary 3, 2025

Blog

Why FDA’s omaveloxolone approval for Friedreich’s ataxia matters

January 10, 2025 Friedreich’s Ataxia (FA) is a rare, genetic, and progressive neurodegenerative disorder. A…

CertaraJanuary 10, 2025

Poster

Preclinical data exposures underpredict clinical physiologically active doses for bispecific T-cell engagers in solid tumors indications; are there better metrics? -insights from a small mechanistic MBMA

CertaraDecember 11, 2024

Poster

Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA, and Serum M-Protein in Subjects With Relapsed/Refractory Multiple Myeloma

CertaraNovember 22, 2024

Poster

A Pharmacokinetic Analysis of Drug Concentration Using a Novel Deep Learning Model

CertaraNovember 22, 2024

Poster

Model-Informed Drug Development Framework for the Development and Dose Optimization of Targeted Radiation Therapies

CertaraNovember 22, 2024

Poster

Oncology MIDD Simulator, A User-Friendly Application for Overall Survival Forecasting in Early Oncology Trials

CertaraNovember 22, 2024

Poster

Population pharmacokinetic modeling of niraparib to assess different absorption models

CertaraNovember 22, 2024

Blog

PBPK Modeling to Support Bioequivalence & Generic Product Approvals

Physiologically-based pharmacokinetic modeling can be used to support bioequivalence (BE) assessment of complex and locally…

CertaraNovember 12, 2024

Publication

A Sequential Population Pharmacokinetic Model of Zilovertamab Vedotin in Patients with Hematologic Malignancies Extrapolated to the Pediatric Population

CertaraNovember 7, 2024

© 2025 Certara. All Rights Reserved. | Privacy policy